Assembly Biosciences, Inc.
ASMB · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.25 | 0.06 | -0.18 | 0.11 |
| FCF Yield | -12.08% | -32.66% | -0.39% | -15.85% |
| EV / EBITDA | -10.60 | -5.18 | -5.96 | -6.33 |
| Quality | ||||
| ROIC | -32.61% | -18.79% | -15.94% | -18.27% |
| Gross Margin | 0.00% | 100.00% | 99.57% | 100.00% |
| Cash Conversion Ratio | 1.65 | 1.64 | 2.66 | 0.04 |
| Growth | ||||
| Revenue 3-Year CAGR | 3,337,845.84% | 3,215,417.08% | 3,179,786.87% | 3,055,171.72% |
| Free Cash Flow Growth | 28.50% | -5,658.97% | 97.33% | 10.94% |
| Safety | ||||
| Net Debt / EBITDA | 1.90 | 2.06 | 3.07 | 2.47 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -817.76 | 0.00 |